# Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies

> **NCT05541341** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 200 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma
- Acute Lymphoblastic Leukemia
- Follicular Lymphoma

## Interventions

- **OTHER:** tisagenlecleucel

## Key facts

- **NCT ID:** NCT05541341
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-23
- **Primary completion:** 2043-11-23
- **Final completion:** 2043-11-23
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05541341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05541341, "Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05541341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*